TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Multicenter, Randomized Study Comparing CNTO 1275 and Etanercept for the Treatment of Moderate to Severe Plaque Psoriasis
Brief Summary: The purpose of this study is to compare the efficacy and safety of CNTO 1275 to etanercept in patients with moderate to severe plaque psoriasis.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Methotrexate, Drug: tocilizumab [RoActemra/Actemra] | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Methotrexate, Drug: tocilizumab [RoActemra/Actemra] | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Methotrexate, Drug: Placebo | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): 1, 2, 3 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: tocilizumab [RoActemra/Actemra]; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: tocilizumab [RoActemra/Actemra]; Assigned to Arm(s): 1
B: Intervention Type: DRUG; Name: Etanercept; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: Etanercept; Assigned to Arm(s): N/A
D: Arm Label: CNTO 1275 45 mg; Type: EXPERIMENTAL; Interventions: Drug: CNTO 1275 45 mg | Arm Label: CNTO 1275 90 mg; Type: EXPERIMENTAL; Interventions: Drug: CNTO 1275 90 mg | Arm Label: Etanercept 50 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Etanercept 50 mg | Intervention Type: DRUG; Name: CNTO 1275 45 mg; Assigned to Arm(s): CNTO 1275 45 mg | Intervention Type: DRUG; Name: CNTO 1275 90 mg; Assigned to Arm(s): CNTO 1275 90 mg | Intervention Type: DRUG; Name: Etanercept 50 mg; Assigned to Arm(s): Etanercept 50 mg

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Multicenter, Randomized Study Comparing CNTO 1275 and Etanercept for the Treatment of Moderate to Severe Plaque Psoriasis
Brief Summary: The purpose of this study is to compare the efficacy and safety of CNTO 1275 to etanercept in patients with moderate to severe plaque psoriasis.


Options:
A: Arm Label: CNTO 1275 45 mg; Type: EXPERIMENTAL; Interventions: Drug: CNTO 1275 45 mg | Arm Label: CNTO 1275 90 mg; Type: EXPERIMENTAL; Interventions: Drug: CNTO 1275 90 mg | Arm Label: Etanercept 50 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Etanercept 50 mg | Intervention Type: DRUG; Name: CNTO 1275 45 mg; Assigned to Arm(s): CNTO 1275 45 mg | Intervention Type: DRUG; Name: CNTO 1275 90 mg; Assigned to Arm(s): CNTO 1275 90 mg | Intervention Type: DRUG; Name: Etanercept 50 mg; Assigned to Arm(s): Etanercept 50 mg
B: Arm Label: 80 mg ixekizumab Dosing Regimen 1; Type: EXPERIMENTAL; Interventions: Drug: 80 mg ixekizumab Dosing Regimen | Arm Label: 80 mg ixekizumab Dosing Regimen 2; Type: EXPERIMENTAL; Interventions: Drug: 80 mg ixekizumab Dosing Regimen | Arm Label: 80 mg ixekizumab Dosing Regimen 3; Type: EXPERIMENTAL; Interventions: Drug: 80 mg ixekizumab Dosing Regimen | Arm Label: 50 mg etanercept; Type: ACTIVE_COMPARATOR; Interventions: Drug: 50 mg etanercept | Arm Label: Placebo for ixekizumab; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: 80 mg ixekizumab Dosing Regimen; Assigned to Arm(s): 80 mg ixekizumab Dosing Regimen 1, 80 mg ixekizumab Dosing Regimen 2, 80 mg ixekizumab Dosing Regimen 3 | Intervention Type: DRUG; Name: 50 mg etanercept; Assigned to Arm(s): 50 mg etanercept | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo for ixekizumab
C: Arm Label: Cohort 1; Type: EXPERIMENTAL; Interventions: Drug: (CP-6890,550) Tofacitinib, Drug: Placebo | Arm Label: Cohort 2; Type: EXPERIMENTAL; Interventions: Drug: (CP-690,550) Tofacitinib, Drug: Placebo | Intervention Type: DRUG; Name: (CP-6890,550) Tofacitinib; Assigned to Arm(s): Cohort 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cohort 1 | Intervention Type: DRUG; Name: (CP-690,550) Tofacitinib; Assigned to Arm(s): Cohort 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cohort 2
D: Arm Label: Placebo BID; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: 5mg BID CP-690,550; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: 10mg BID CP-690,550; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo BID | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): 5mg BID CP-690,550 | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): 10mg BID CP-690,550

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Multicenter, Randomized Study Comparing CNTO 1275 and Etanercept for the Treatment of Moderate to Severe Plaque Psoriasis
Brief Summary: The purpose of this study is to compare the efficacy and safety of CNTO 1275 to etanercept in patients with moderate to severe plaque psoriasis.


Options:
A: Arm Label: Cohort 1; Type: EXPERIMENTAL; Interventions: Drug: (CP-6890,550) Tofacitinib, Drug: Placebo | Arm Label: Cohort 2; Type: EXPERIMENTAL; Interventions: Drug: (CP-690,550) Tofacitinib, Drug: Placebo | Intervention Type: DRUG; Name: (CP-6890,550) Tofacitinib; Assigned to Arm(s): Cohort 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cohort 1 | Intervention Type: DRUG; Name: (CP-690,550) Tofacitinib; Assigned to Arm(s): Cohort 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cohort 2
B: Arm Label: Tildrakizumab 200 mg; Type: EXPERIMENTAL; Interventions: Drug: Tildrakizumab 200 mg, Drug: Matching Placebo | Arm Label: Tildrakizumab 100 mg; Type: EXPERIMENTAL; Interventions: Drug: Tildrakizumab 100 mg, Drug: Matching Placebo | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Tildrakizumab 200 mg, Drug: Tildrakizumab 100 mg, Drug: Matching Placebo | Intervention Type: DRUG; Name: Tildrakizumab 200 mg; Assigned to Arm(s): Placebo, Tildrakizumab 200 mg | Intervention Type: DRUG; Name: Tildrakizumab 100 mg; Assigned to Arm(s): Placebo, Tildrakizumab 100 mg | Intervention Type: DRUG; Name: Matching Placebo; Assigned to Arm(s): Placebo, Tildrakizumab 100 mg, Tildrakizumab 200 mg
C: Arm Label: Placebo/Adalimumab; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo, Biological: Adalimumab | Arm Label: Adalimumab; Type: ACTIVE_COMPARATOR; Interventions: Biological: Adalimumab | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo/Adalimumab | Intervention Type: BIOLOGICAL; Name: Adalimumab; Assigned to Arm(s): Adalimumab, Placebo/Adalimumab
D: Arm Label: CNTO 1275 45 mg; Type: EXPERIMENTAL; Interventions: Drug: CNTO 1275 45 mg | Arm Label: CNTO 1275 90 mg; Type: EXPERIMENTAL; Interventions: Drug: CNTO 1275 90 mg | Arm Label: Etanercept 50 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Etanercept 50 mg | Intervention Type: DRUG; Name: CNTO 1275 45 mg; Assigned to Arm(s): CNTO 1275 45 mg | Intervention Type: DRUG; Name: CNTO 1275 90 mg; Assigned to Arm(s): CNTO 1275 90 mg | Intervention Type: DRUG; Name: Etanercept 50 mg; Assigned to Arm(s): Etanercept 50 mg

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Multicenter, Randomized Study Comparing CNTO 1275 and Etanercept for the Treatment of Moderate to Severe Plaque Psoriasis
Brief Summary: The purpose of this study is to compare the efficacy and safety of CNTO 1275 to etanercept in patients with moderate to severe plaque psoriasis.


Options:
A: Arm Label: Investigational drug - Dose 1; Type: EXPERIMENTAL; Interventions: Drug: ACT-128800 | Arm Label: Investigational drug - Dose 2; Type: EXPERIMENTAL; Interventions: Drug: ACT-128800 | Arm Label: Matching placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: ACT-128800; Assigned to Arm(s): Investigational drug - Dose 1, Investigational drug - Dose 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Matching placebo
B: Arm Label: Bimekizumab dosage regimen 1; Type: EXPERIMENTAL; Interventions: Drug: Bimekizumab, Other: Placebo | Arm Label: Bimekizumab dosage regimen 2; Type: EXPERIMENTAL; Interventions: Drug: Bimekizumab, Other: Placebo | Arm Label: Secukinumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bimekizumab, Drug: Secukinumab | Intervention Type: DRUG; Name: Bimekizumab; Assigned to Arm(s): Bimekizumab dosage regimen 1, Bimekizumab dosage regimen 2, Secukinumab | Intervention Type: DRUG; Name: Secukinumab; Assigned to Arm(s): Secukinumab | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Bimekizumab dosage regimen 1, Bimekizumab dosage regimen 2
C: Arm Label: CNTO 1275 45 mg; Type: EXPERIMENTAL; Interventions: Drug: CNTO 1275 45 mg | Arm Label: CNTO 1275 90 mg; Type: EXPERIMENTAL; Interventions: Drug: CNTO 1275 90 mg | Arm Label: Etanercept 50 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Etanercept 50 mg | Intervention Type: DRUG; Name: CNTO 1275 45 mg; Assigned to Arm(s): CNTO 1275 45 mg | Intervention Type: DRUG; Name: CNTO 1275 90 mg; Assigned to Arm(s): CNTO 1275 90 mg | Intervention Type: DRUG; Name: Etanercept 50 mg; Assigned to Arm(s): Etanercept 50 mg
D: Intervention Type: DRUG; Name: adalimumab; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Family Lifestyle Overweight Prevention Program: Evaluation of a Weight Management Program for Mexican American Youth
Brief Summary: The purpose of the study was to design a weight management program for Mexican American youth and to determine the effectiveness of the program for weight management compared to a self help program.

1. At the end of 6 months, individuals randomly assigned to Intensive Intervention (II) (instructor/trainer led intervention) will lose more weight than individuals assigned to Self Help (SH) only.
2. At the end of 1 year, individuals randomly assigned to II will maintain their weight losses better than individuals assigned to SH.

Secondary hypotheses will include examination of main effects and interactions at the end of 6 months with the following secondary dependent measures: treatment adherence (e.g., attendance, food diaries, exercise diaries), blood levels, changes in percent body fat, overall psychological functioning (PEDS-QL 4.0), and eating behaviors as assessed by food frequency checklists.


Options:
A: Intervention Type: BEHAVIORAL; Name: FLOW; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: SelfHelp; Assigned to Arm(s): N/A
B: Intervention Type: BEHAVIORAL; Name: Physical activity and diet; Assigned to Arm(s): N/A
C: Arm Label: control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Educational strategy; Type: EXPERIMENTAL; Interventions: Behavioral: Educational strategy | Arm Label: Screening strategy; Type: EXPERIMENTAL; Interventions: Behavioral: Screening strategy | Arm Label: Environmental strategy; Type: EXPERIMENTAL; Interventions: Other: Environmental strategy | Arm Label: Educational and Screening strategies; Type: EXPERIMENTAL; Interventions: Behavioral: Educational strategy, Behavioral: Screening strategy | Arm Label: Screening and Environmental strategies; Type: EXPERIMENTAL; Interventions: Behavioral: Screening strategy, Other: Environmental strategy | Arm Label: Educational and Environmental strategies; Type: EXPERIMENTAL; Interventions: Behavioral: Educational strategy, Other: Environmental strategy | Arm Label: the three strategies; Type: EXPERIMENTAL; Interventions: Behavioral: Educational strategy, Behavioral: Screening strategy, Other: Environmental strategy | Intervention Type: BEHAVIORAL; Name: Educational strategy; Assigned to Arm(s): Educational and Environmental strategies, Educational and Screening strategies, Educational strategy, the three strategies | Intervention Type: BEHAVIORAL; Name: Screening strategy; Assigned to Arm(s): Educational and Screening strategies, Screening and Environmental strategies, Screening strategy, the three strategies | Intervention Type: OTHER; Name: Environmental strategy; Assigned to Arm(s): Educational and Environmental strategies, Environmental strategy, Screening and Environmental strategies, the three strategies
D: Intervention Type: BEHAVIORAL; Name: Incorporating More Physical Activity and Calcium in Teens (IMPACT) Program; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Family Lifestyle Overweight Prevention Program: Evaluation of a Weight Management Program for Mexican American Youth
Brief Summary: The purpose of the study was to design a weight management program for Mexican American youth and to determine the effectiveness of the program for weight management compared to a self help program.

1. At the end of 6 months, individuals randomly assigned to Intensive Intervention (II) (instructor/trainer led intervention) will lose more weight than individuals assigned to Self Help (SH) only.
2. At the end of 1 year, individuals randomly assigned to II will maintain their weight losses better than individuals assigned to SH.

Secondary hypotheses will include examination of main effects and interactions at the end of 6 months with the following secondary dependent measures: treatment adherence (e.g., attendance, food diaries, exercise diaries), blood levels, changes in percent body fat, overall psychological functioning (PEDS-QL 4.0), and eating behaviors as assessed by food frequency checklists.


Options:
A: Arm Label: ACTION PAC Behavioral Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: ACTION PAC, Behavioral: Communication with parents | Arm Label: Comparison; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Communication with parents | Intervention Type: BEHAVIORAL; Name: ACTION PAC; Assigned to Arm(s): ACTION PAC Behavioral Intervention | Intervention Type: BEHAVIORAL; Name: Communication with parents; Assigned to Arm(s): ACTION PAC Behavioral Intervention, Comparison
B: Arm Label: Intervention group; Type: EXPERIMENTAL; Interventions: Behavioral: Challenge! | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Challenge!; Assigned to Arm(s): Intervention group
C: Arm Label: HEALTH[e]TEEN; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: HEALTH[e]TEEN | Arm Label: HEALTH[e]TEEN + CST; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: HEALTH[e]TEEN + CST | Intervention Type: BEHAVIORAL; Name: HEALTH[e]TEEN; Assigned to Arm(s): HEALTH[e]TEEN | Intervention Type: BEHAVIORAL; Name: HEALTH[e]TEEN + CST; Assigned to Arm(s): HEALTH[e]TEEN + CST
D: Intervention Type: BEHAVIORAL; Name: FLOW; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: SelfHelp; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Rehabilitation of Patients With Modic Changes in the Lumbar Spine - a Randomized Controlled Trial
Brief Summary: The purpose of this study is to compare patients with low back pain (LBP) and Modic Changes from The Backcenter Funen, Ringe:

1. To compare the effect of two types of non-operative treatments:

   A. exercise and advice to be physically active

   B. restitution and advice not to overload the spine
2. To investigate if the results of the treatment are influenced by gender, age, smoking, and physical load.


Options:
A: Arm Label: Neurodynamic group; Type: EXPERIMENTAL; Interventions: Procedure: Neurodynamic Group | Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Neurodynamic Group; Assigned to Arm(s): Neurodynamic group
B: Arm Label: Yoga; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Weekly yoga classes | Arm Label: Physical Therapy; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Individual physical therapy treatment | Arm Label: Education; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Education | Intervention Type: BEHAVIORAL; Name: Weekly yoga classes; Assigned to Arm(s): Yoga | Intervention Type: BEHAVIORAL; Name: Individual physical therapy treatment; Assigned to Arm(s): Physical Therapy | Intervention Type: BEHAVIORAL; Name: Education; Assigned to Arm(s): Education
C: Arm Label: Exercise and advise to stay active; Type: ACTIVE_COMPARATOR; Interventions: Other: Exercise | Arm Label: Rest and use of flexible lumbar belt; Type: EXPERIMENTAL; Interventions: Other: Restitution | Intervention Type: OTHER; Name: Exercise; Assigned to Arm(s): Exercise and advise to stay active | Intervention Type: OTHER; Name: Restitution; Assigned to Arm(s): Rest and use of flexible lumbar belt
D: Arm Label: Yoga; Type: EXPERIMENTAL; Interventions: Behavioral: Yoga Therapy for CLBP | Arm Label: Delayed Treatment Control - Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Yoga Therapy for CLBP; Assigned to Arm(s): Yoga

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Rehabilitation of Patients With Modic Changes in the Lumbar Spine - a Randomized Controlled Trial
Brief Summary: The purpose of this study is to compare patients with low back pain (LBP) and Modic Changes from The Backcenter Funen, Ringe:

1. To compare the effect of two types of non-operative treatments:

   A. exercise and advice to be physically active

   B. restitution and advice not to overload the spine
2. To investigate if the results of the treatment are influenced by gender, age, smoking, and physical load.


Options:
A: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Other: Exercise | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Exercise; Assigned to Arm(s): Intervention
B: Arm Label: Spinal orthosis group; Type: ACTIVE_COMPARATOR; Interventions: Device: Spinal orthosis Spinomed | Arm Label: Equipment training group; Type: ACTIVE_COMPARATOR; Interventions: Other: Equipment training | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Spinal orthosis Spinomed; Assigned to Arm(s): Spinal orthosis group | Intervention Type: OTHER; Name: Equipment training; Assigned to Arm(s): Equipment training group
C: Arm Label: Exercise and advise to stay active; Type: ACTIVE_COMPARATOR; Interventions: Other: Exercise | Arm Label: Rest and use of flexible lumbar belt; Type: EXPERIMENTAL; Interventions: Other: Restitution | Intervention Type: OTHER; Name: Exercise; Assigned to Arm(s): Exercise and advise to stay active | Intervention Type: OTHER; Name: Restitution; Assigned to Arm(s): Rest and use of flexible lumbar belt
D: Arm Label: Physical Activity; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Physical Activity | Arm Label: Successful Aging; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Successful Aging | Intervention Type: BEHAVIORAL; Name: Physical Activity; Assigned to Arm(s): Physical Activity | Intervention Type: BEHAVIORAL; Name: Successful Aging; Assigned to Arm(s): Successful Aging

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Assess the Efficacy and Safety of Daily Oral Administration of 5mg and 10mg VESIcare® for the Treatment of Urgency Associated With Overactive Bladder
Brief Summary: The purpose is to evaluate the efficacy of 5 and 10mg VESIcare® (solifenacin succinate) in patients with urgency who have overactive bladder syndrome.


Options:
A: Arm Label: Fesoterodine; Type: EXPERIMENTAL; Interventions: Drug: fesoterodine fumarate | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: Tolterodine; Type: ACTIVE_COMPARATOR; Interventions: Drug: tolterodine tartrate | Intervention Type: DRUG; Name: fesoterodine fumarate; Assigned to Arm(s): Fesoterodine | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: tolterodine tartrate; Assigned to Arm(s): Tolterodine
B: Arm Label: Placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Solifenacin Succinate; Type: EXPERIMENTAL; Interventions: Drug: Solifenacin Succinate | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Solifenacin Succinate; Assigned to Arm(s): Solifenacin Succinate
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: VESIcare® | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: VESIcare®; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 2
D: Intervention Type: DRUG; Name: YM178; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effectiveness of Artemether-Lumefantrine Treatment Provided by Community Health Worker Against Uncomplicated Malaria in Children Under 5 Years of Age in Tanzania
Brief Summary: The purpose of this clinical trial is to assess the effectiveness of artemether-lumefantrine (Coartem®) treatment provided by community health workers against uncomplicated malaria in children under 5 years of age in Kibaha District, Tanzania, during an extended follow-up of 42 days. The hypothesis is that artemether-lumefantrine treatment provided by community health workers will result in less than 85% PCR-corrected parasitological effectiveness by day 42, mainly due to partial non-compliance to full standard 6-dose regimen of the drug.


Options:
A: Arm Label: SP and amodiaquine; Type: ACTIVE_COMPARATOR; Interventions: Drug: SP plus amodiaquine | Arm Label: SP placebo plus amodiaquine placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: SP placebo plus amodiaquine placebo | Intervention Type: DRUG; Name: SP plus amodiaquine; Assigned to Arm(s): SP and amodiaquine | Intervention Type: DRUG; Name: SP placebo plus amodiaquine placebo; Assigned to Arm(s): SP placebo plus amodiaquine placebo
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Coartem and amoxicillin | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Coartem | Intervention Type: DRUG; Name: Coartem and amoxicillin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Coartem; Assigned to Arm(s): 2
C: Intervention Type: DRUG; Name: artemether-lumefantrine; Assigned to Arm(s): N/A
D: Intervention Type: BEHAVIORAL; Name: Provision of antimalarial treatment at home; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Weight Loss and Cardiovascular Disease (CVD) Prevention Via a Whole Grain Diet in Men and Women With Metabolic Syndrome
Brief Summary: The purpose of this study is to determine if intake of whole grain foods as part of a hypocaloric diet enhances weight loss and improves cardiovascular disease risk factors in men and women with metabolic syndrome.


Options:
A: Intervention Type: BEHAVIORAL; Name: Whole Grain Foods; Assigned to Arm(s): N/A
B: Arm Label: Low Glycemic Index Diet; Type: EXPERIMENTAL; Interventions: Other: Low Glycemic Index diet | Arm Label: High Fiber Diet; Type: ACTIVE_COMPARATOR; Interventions: Other: High Cereal Fibre Diets | Intervention Type: OTHER; Name: Low Glycemic Index diet; Assigned to Arm(s): Low Glycemic Index Diet | Intervention Type: OTHER; Name: High Cereal Fibre Diets; Assigned to Arm(s): High Fiber Diet
C: Intervention Type: DIETARY_SUPPLEMENT; Name: Ls-33; Assigned to Arm(s): N/A
D: Arm Label: Refined grain; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Refined grain | Arm Label: Whole grain diet; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Whole grain diet | Intervention Type: DIETARY_SUPPLEMENT; Name: Whole grain diet; Assigned to Arm(s): Whole grain diet | Intervention Type: DIETARY_SUPPLEMENT; Name: Refined grain; Assigned to Arm(s): Refined grain

Answer: A